Study of EPI-003 for chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This trial tests an experimental medicine, EPI-003, for people with chronic hepatitis B who are already on a stable antiviral treatment. It may help control the virus better or even achieve a functional cure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have a confirmed diagnosis of chronic hepatitis B (CHB).
- You must have been on a stable dose of nucleoside or nucleotide analog therapy (like tenofovir or entecavir) for at least 6 months, and plan to keep taking the same dose during the study.
- You cannot have been diagnosed with liver cancer or cirrhosis (severe liver scarring).
- You must not have any other major health conditions (like advanced heart, kidney, or lung disease).
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called EPI-003 for people with chronic hepatitis B who are already taking antiviral pills (like entecavir or tenofovir). The goal is to see if adding EPI-003 can further lower the virus and help the immune system. You must continue your current antiviral during the study.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
This trial tests a new medication called ACT201 in two parts: one for healthy volunteers and one for people with chronic hepatitis B. For participants with hepatitis B, the drug may help control the infection, and the study will check its safety and how well it works.
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.